⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for PRolaCT - Three Prolactinoma RCTs

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: PRolaCT - Three Prolactinoma RCTs

Official Title: PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials

Study ID: NCT04107480

Study Description

Brief Summary: This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (\>2 years) period of pretreatment with a dopamine agonist is superior to standard care for several outcome parameters. The main objectives are to investigate this for quality of life and remission rate. The secondary objectives are to investigate this for biochemical disease control, recurrence rates, clinical symptom control, tumor shrinkage on MRI, pituitary functioning, the occurrence of adverse reactions to treatment, disease burden, and cost-effectiveness.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Amsterdam University Medical Center, loc. AMC, Amsterdam-Zuidoost, Noord-Holland, Netherlands

Reinier de Graaf Gasthuis, Delft, Zuid-Holland, Netherlands

Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands

Contact Details

Name: Nienke R Biermasz, MD, prof.

Affiliation: Endocrinologist LUMC

Role: PRINCIPAL_INVESTIGATOR

Name: Wouter R van Furth, MD, PhD

Affiliation: Neurosurgeon LUMC

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: